{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:35:32Z","timestamp":1791920132943,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disease with limited symptomatic treatment options. Aggregation of \u03b1\u2010synuclein in oligodendrocytes is believed to be a central mechanism of the neurodegenerative process. PD01A and PD03A are 2 novel therapeutic vaccine candidates containing short peptides as antigenic moieties that are designed to induce a sustained antibody response, specifically targeting pathogenic assemblies of \u03b1\u2010synuclein. The objectives of the current study were to evaluate primarily the safety and tolerability of PD01A and PD03A in patients with early MSA. Thirty patients (11 women) were randomized to receive 5 subcutaneous injections of either PD01A (n = 12), PD03A (n = 12), or placebo (n = 6) in this patient\u2010 and examiner\u2010blinded, placebo\u2010controlled, 52\u2010week phase 1 clinical trial (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrial.gov\">ClinicalTrial.gov<\/jats:ext-link>\n                    identifier: NCT02270489). Immunogenicity and clinical scores were assessed as secondary objectives. Twenty\u2010nine patients reported a total of 595 treatment\u2010emergent adverse events (mild or moderate, n = 555; severe, n = 40). Treatment\u2010related adverse events included 190 injection\u2010site reactions typically observed in vaccination trials with similar per\u2010subject incidence in the treatment groups over time. Sustained IgG titers were observed in the PD01A\u2010treated group, and 89% of treated patients developed a PD01\u2010specific antibody response after receiving all injections. Induced antibodies displayed clear reactivity to the \u03b1\u2010synuclein target epitope. Titers and antibody responder rate (58%) were lower in the PD03A\u2010treated group. In conclusion, both PD01A and PD03A were safe and well tolerated. PD01A triggered a rapid and long\u2010lasting antibody response that specifically targeted the \u03b1\u2010synuclein epitope. \u00a9 2020 The Authors.\n                    <jats:italic>Movement Disorders<\/jats:italic>\n                    published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\n                  <\/jats:p>","DOI":"10.1002\/mds.28218","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T13:39:00Z","timestamp":1599140340000},"page":"1957-1965","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["A Phase 1 Randomized Trial of Specific Active\n                    <scp>\u03b1\u2010Synuclein<\/scp>\n                    Immunotherapies\n                    <scp>PD01A<\/scp>\n                    and\n                    <scp>PD03A<\/scp>\n                    in Multiple System Atrophy"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-7527","authenticated-orcid":false,"given":"Wassilios G.","family":"Meissner","sequence":"first","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e CHU Bordeaux  Bordeaux France"},{"name":"Univ. de Bordeaux CNRS, IMN, UMR 5293  Bordeaux F\u201033000 France"},{"name":"CNRS, IMN, UMR 5293  Bordeaux F\u201033000 France"},{"name":"Dept. Medicine University of Otago, Christchurch, and New Zealand Brain Research Institute  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Pavy\u2010Le","family":"Traon","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e CHU Toulouse, Toulouse\u2013 INSERM U 1048 Institut des Maladies M\u00e9taboliques et Cardiovasculaires  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Foubert\u2010Samier","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e CHU Bordeaux  Bordeaux France"},{"name":"INSERM U897, Public Health and Development Institute (ISPED) Bordeaux University  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergana","family":"Galabova","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Galitzky","sequence":"additional","affiliation":[{"name":"Clinical Investigation Center CIC1436, French Reference Centre for MSA University Hospital Toulouse, University Toulouse  France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kutzelnigg","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Laurens","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"L\u00fchrs","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Medori","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7200-0139","authenticated-orcid":false,"given":"Patrice","family":"P\u00e9ran","sequence":"additional","affiliation":[{"name":"ToNIC, Toulouse NeuroImaging Center Universit\u00e9 de Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Sabatini","sequence":"additional","affiliation":[{"name":"Institute of Neuroradiology University Magna Graecia  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Vergnet","sequence":"additional","affiliation":[{"name":"Service de Neurologie, CRMR Atrophie Multisyst\u00e9matis\u00e9e CHU Bordeaux  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Volc","sequence":"additional","affiliation":[{"name":"Study Center PROSENEX Ambulatorium Betriebs GesmbH at Confraternit\u00e4t\u2010Privatklinik  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Poewe","sequence":"additional","affiliation":[{"name":"Department of Neurology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Schneeberger","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnther","family":"Staffler","sequence":"additional","affiliation":[{"name":"AFFiRiS AG  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Toulouse 3, CHU de Toulouse, INSERM, Centre de Reference AMS, Service de Neurologie et de Pharmacologie Clinique Centre d'Investigation Clinique CIC1436, R\u00e9seau NS\u2010Park\/FCRIN et Centre of Excellence for Neurodegenerative Disorders (COEN) de Toulouse  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the AFF009 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1311488"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2017.12.008"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27894"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(89)90219-0"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.2.235"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(98)00504-7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2011.01234.x"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2014.03.021"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0730-6"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124129"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00006-X"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26377"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26568"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-015-0008-9"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1256-4"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000324625.00404.15"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-35761-6.00002-X"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27738"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1487"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.28218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:03:27Z","timestamp":1760954607000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.28218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1002\/mds.28218"],"URL":"https:\/\/doi.org\/10.1002\/mds.28218","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"2020-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}